Amides derived from the esters of 1-piperazine propionic acid, their method of preparation and their application to therapeutics

ABSTRACT

IN WHICH R IS ALKYL HAVING 1 TO 4 CARBON ATOMS. THE COMPOUNDS ARE MADE BY REACTING 3,4,5-TRIMETHOXY CINNAMOYL HALIDE WITH AN ESTER OF 1-PIPERAZINE PROPIONIC ACID IN THE PRESENCE OF AN ALKALINE AGENT. THE COMPOUNDS POSSESS PROPERTIES OF CORONARY DILATION WITH A DIMINUTION OF THE CARDIAC CONSUMPTION OF OXYGWEN AS WELL AS HYPOTENSIVE, VASOLIDATOR AND B-INHIBITOR PROPERTIES.   PIPERAZINE   1-(R-OOC-(CH2)2-),4-((3,4,5-TRI(CH3-O-)PHENYL)-CH=CH-CO-)-   COMPOUNDS OF THE FORMULA

United States Patent Office 3,753,984 Patented Aug. 21, 1973 ABSTRACT OF THE DISCLOSURE Compounds of the formula in which R is alkyl having 1 to 4 carbon atoms.

The compounds are made by reacting 3,4,5-trimethoxy cinnamoyl halide with an ester of l-piperazine propionic acid in the presence of an alkaline agent.

The compounds possess properties of coronary dilation with a diminution of the cardiac consumption of oxygen as well as hypotensive, vasodilator and [s -inhibitor properties.

kaline agent capable of combining with the hydracid formed during the reaction.

The following preparation is given as anon-limiting example to explain the invention.

1-(3',4',5'-trimethoxycinnamoyl) 4-(ethoxy carbonyl ethyl) piperazine maleate (code number 6924) 51 g. of trimethoxy cinnamoyl chloride and 25 g. of sodium bicarbonate are dissolved in 300 ml. of ethyl acetate. The temperature of the mixture is raised to 65 C., and then 37 g. of l-piperazine propionic acid ethyl ester are introduced under stirring. The back flow is then maintained for an hour. After cooling, 200 ml. of water are added. The organic phase is decanted and then it is concentrated. The residue obtained is crystallised in a mixture of ethyl acetate and isopropyl ether.

The product obtained is dissolved in absolute ethanol and processed by the equivalent proportion of maleic acid. The maleate obtained is centrifuged and crystallised in ethanol.

Melting point: 146 C. Yield: 50% Empirical formua: C H N O Elementary analysis.Calculated (percent): C, 57.46; H, 6.56; H, 5.36. Obtained (percent): C, 57.55; H, 6.36; N, 5.22.

The compounds recorded in the following Table I were prepared according to the invention.

TABLE I Elementary analysis (percent) Melting Calculated Obtained I Code Empirical Yield point number R Form formula Recrystalhsatlon solvent (percent) C.) C H N C H N 69339 CHs-(CHW {iiiiiar i::'e.yag.uaeaii: E5325 fffifijjIiiIiIIIj: 45 165 59-80 M6 M19 58-85 6325s.::eiagaaaai: 3353.33???fffffffiiiffiiiz} 51 160 56-68 56.84 W 70102 CHa-(CHrDr- Maleate--- CzeHanNzOro 6 144 58. 20 6.76 5.22 58.01 6.73 5.08

70153 CH; Ma1e8te. CzuHaaNaOw n: 60 151 58.20 6.76 5.22 58.01 6.85 5. 36

/CH-- CH;

The present invention has for its object new amides derived from the esters of l-piperazine propionic acid, their method of preparation and their application to therapeutics.

The new compounds according to the invention correspond to the general formula:

H3O (I) H C0CHCHC O-N N-CH -ClL-C 00R in which R represents an alkyl chain having from 1 to 4 carbon atoms.

The method of the invention consists in causing a 3,4, S-trimethoxy cinnamoyl halide whose formula is:

in which X represents a halogen atom, to react with an ester of l-piperazine propionic acid, whose formula is:

H-N NCHr-C Hr-C O 0 R (III) in which R has the same meaning as in Formula I operating in an organic solvent and in the presence of an al- The compounds of Formua I were tested on the laboratory animal and showed, in particular, properties of coronaryl dilatation with a diminution of the cardiac consumption of oxygen, as well as hypotensive, vasodilatator and B-inhibitor properties.

1". Properties of coronarydilatation and action on the consumption of oxygen The compounds of Formula I are capable, by intravenous perfusion or by intraduodenal administration, of increasing the flow of the coronary sinus venosus in an anaesthetised dog. Moreover, they increase the p0 of the blood of the coronary sinus venosus and reduce the myocardial extraction of oxygen.

As examples, the results obtained with a certain number of compounds of Formula I are recorded in the following Table II:

TAB LE II Increase 01' the Dose adminls- Increase in the p02 of the blood tered to the dog flow of sinus of the sinus Code number (mg./kg./IV) venosus (percent)venosus (percent) 2 Hypotensive properties The compounds of Formula I injected intravenously cause a drop of the arterial pressure in an anaesthetised cat.

As examples, the results obtained with a certain number of compounds of Formula I are recorded in Table III below:

TABLE III Dose admlnls- Dlmlnution of tered to the cat the arterial pres- Code number (mg./kg./IV) sure (percent) 3. Vasodilatatory action Administered intra-arterially, the compounds of Formula I greatly increase the flow in the artery where the injection was carried out. This action has been studied in an anaesthetised dog whose femoral artery flow was measured by a rotameter placed on a tapping coming from the homolateral carotid artery and supplying the femoral artery.

As examples, the results obtained with a certain number of compounds of Formula I are recorded in the following table IV:

TABLE IV Dose administered to the dog Percentage of Code number (mgJkgJIA) effectiveness 4. B-Inhibitory action On the isolated auricle of a guinea-pig, the compounds of Formula I are capable of opposing the increase in frequency produced by isoprenaline.

As an example, compound number 6924 gave, with a concentration of 0.02 mg./ml., an effectiveness percentage of 60%.

As is clear from the above results and from those re corded in Table V below, the dilference between pharmacologically active doses and lethal doses is sufficiently great to allow the compounds of Formula I to be used in therapeutics.

4 TABLE V BL in the mouse (mg./kg./ IV 265 Code number in which R is alkyl having 1 to 4 carbon atoms, and the pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 in which R is selected from the group consisting of methyl, ethyl, propyl, isopropyl and butyl.

References Cited UNITED STATES PATENTS 7/1967 Delalande 260240 I 6/1971 Fauran et al. 260-240 J OTHER REFERENCES Fauran et al., Chim. Ther. 1969, pp. 290-2. Huguet et a1., Chim. Ther. 1969, p. 293.

JOHN D. RANDOLPH, Primary Examiner U.S. Cl. X.R.

UNITED STATES PATENT OFFICE CERTH CATE 0F QQECTIQN Patent No. 3 753 9 4 Dated August 21, 1973 Claude P. Fauran, Michel J. Turin, Inventor(s Guy MgRaynaud and Bernard M. Pourrias It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Foreign Application Priority Data June 3, 1970 France -.-70. 20278 Signed and sealed this 12th day of February 1974.

(SEAL) Attest:

EDWARIlM.FLETQHER,JR. C a MARSHALL DANN Attestlng OfflCeI Commissioner of Patents )RM PO-IOSO (10-69) USCOMM-DC 60376-F'69 U,S. GOVERNMENT PRINTING OFFICE: 1989 0-366-334. 

